|Videos|March 30, 2023

Placing Context Around Public Health Messaging, Addressing Infection Prevention for Candida auris

The CDC’s recent warning of the rising incidence rates of the fungal infection is cause for concern, but understanding which patients and settings are at a higher risk is equally as important. The lead author in the CDC’s recent C auris study offers some insights for both medical institutions and the general public.


One thing the media does very well is quickly disseminate the news to the public; however, the messaging is not always comprehensive and can be either misleading or sensational, especially when people are just reading headlines or scanning articles. Case in point is the recent CDC warning about the fungal infection, Candida auris. Some news outlets covered it with headlines to the effect of “Deadly Fungus,” or “Cases of Antifungal Resistant Deadly Infection Spreading.”

Yes, both types of headlines are factual, but the context of who is being affected and how many people are actually succumbing to this fungal infection is lost in translation. It is important to note that C auris is mostly limited to people who are older, have weakened immune systems, are experiencing multiple medical problems, and are either hospitalized or in long-term care nursing facilities (LTCF) where these infections can colonize easily.

Meghan Lyman, MD, medical officer, Mycotic Diseases Branch, CDC, and her colleagues coauthored a study, which was published in the Annals of Internal Medicine, looking at the CDC surveillance data tracking the incidence rates of C auris. Lyman points out to the public and providers there is cause for concern, but mainly in these facilities and with these patient populations.

“People with Candida auris are very sick at baseline and require high acuity care,” said Lyman. “These are patients who are on ventilators, have invasive medical devices like central lines, feeding tubes, urinary catheters. They've often had exposure to many antibiotics and antifungal medications. And they've often had long or frequent stays in healthcare facilities. Generally, healthy people are considered low-risk for getting Candida auris and there’s not evidence that transmission in the community is a concern. Transmission mostly occurs in healthcare settings.”

Lyman explains cases increased dramatically, (95% in 2021), and there is a growing resistance to echinocandins, which is a first line of therapy for C auris. She also says the keys to stem colonization and further spread are comprehensive testing and infection prevention control measures.

“These findings emphasize that improved detection and infection control are urgently needed to prevent further spread, and without increased efforts to do this, C auris is going to continue to spread across the US and become endemic like other superbugs,” Lyman said.

The CDC stresses the importance of these medical facilities being proactive in their approach to prevention. “Implementing these practices effectively and ensuring there’s good compliances is important but not always easy. It takes a lot of work and investment of resources,” Lyman stated.

Contagion spoke to Lyman who offered further considerations for the public and medical institutions to know, how the CDC is continuing its work with understanding and preventing C auris, and the resources they are making available.




Related to this article

How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.